Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 62 of 62 results for attention deficit hyperactivity disorder

  1. Social and emotional wellbeing: early years (PH40)

    This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.

    Public health guideline
    Published
    24 October 2012
    View recommendations

    Sections for PH40

  2. Attention deficit disorder

    All NICE products on attention deficit disorder. Includes any guidance and quality standards.

    Topic page

  3. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (DG60)

    We have moved Diagnostics guidance 60 to become HealthTech guidance 729. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Transcutaneous electrical stimulation of the trigeminal nerve for ADHD (IPG748)

    We have moved interventional procedures guidance 748 to become HealthTech guidance 653. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  6. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guidance

  7. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  8. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

    This evidence summary has been withdrawn because licensed products are now available.

    Withdrawn advice

  9. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  10. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This advice has been updated and replaced by NICE healthtech guidance 729.

    Withdrawn advice

  11. Methylphenidate for the treatment of attention deficit hyperactivity disorder in children and adolescents (TA13)

    This guidance has been replaced by NICE technology appraisal guidance 98 [Replaced by NICE guideline NG87].  

    Withdrawn guidance

  12. Attention deficit hyperactivity disorder: diagnosis and management (CG72)

    This guidance has been updated and replaced by NICE guideline NG87.

    Withdrawn guideline